{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:26:57Z","timestamp":1787678817217,"version":"build-2784847793"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>It is urgently necessary to reduce the adverse effects of chemotherapy while maintaining their cure high rates for children with acute lymphoblastic leukemia (ALL). The present study aimed to determine whether the dose intensity of daunorubicin during the remission-induction phase could be reduced for low-risk patients with ALL. A total of 2396 eligible patients, who participated in CCCG-ALL-2015 study and were provisionally assigned to the low-risk group, were included and divided into single-dose group and double-dose group according to the dosage of daunorubicin during the remission-induction phase. For patients with <jats:italic>ETV6-RUNX1<\/jats:italic> positive ALL or hyperdiploidy ALL, there were no significant differences in outcomes between the two groups. For other patients, the 5-year event-free survival rate was significantly better and the 5-year cumulative risk of any relapse was significantly lower in the double-dose group compared with the single-dose group. Both the 5-year overall survival rate and the risk of early deaths were not significantly different between the two groups. Our results suggested that only B-lineage ALL patients with <jats:italic>ETV6-RUNX1<\/jats:italic> positivity or hyperdiploidy who achieved an early negative minimal residual disease status were suitable candidates for dosage reduction of daunorubicin during the remission-induction phase.<\/jats:p><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>http:\/\/www.chictr.org.cn\/showproj.aspx?proj=10115<\/jats:uri>, identifier ChiCTR-IPR-14005706.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.911567","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T05:05:18Z","timestamp":1654578318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children\u2019s Cancer Group"],"prefix":"10.3389","volume":"12","author":[{"given":"Yong","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Kwan","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changda","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.103507","article-title":"Dexamethasone (6 Mg\/M2\/Day) and Prednisolone (60 Mg\/M2\/Day) Were Equally Effective as Induction Therapy for Childhood Acute Lymphoblastic Leukemia in the EORTC CLG 58951 Randomized Trial","volume":"99","author":"Domenech","year":"2014","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24273","article-title":"Doxorubicin or Daunorubicin Given Upfront in a Therapeutic Window Are Equally Effective in Children With Newly Diagnosed Acute Lymphoblastic Leukemia. A Randomized Comparison in Trial Coall 07-03","volume":"60","author":"Escherich","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01692","article-title":"Improved Cns Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5020","article-title":"Triple Intrathecal Therapy Alone With Omission of Cranial Radiation in Children With Acute Lymphoblastic Leukemia","volume":"32","author":"Liu","year":"2014","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone Vs Prednisone in Induction Treatment of Pediatric All: Results of the Randomized Trial Aieop-Bfm All 2000","volume":"127","author":"M\u00f6ricke","year":"2016","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study All10 From the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.265","article-title":"Results of Nopho All2008 Treatment for Patients Aged 1\u201345 Years With Acute Lymphoblastic Leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented Post-Remission Therapy for a Minimal Residual Disease-Defined High-Risk Subgroup of Children and Young People With Clinical Standard-Risk and Intermediate-Risk Acute Lymphoblastic Leukaemia (Ukall 2003): A Randomised Controlled Trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016584","article-title":"Refining Risk Classification in Childhood B Acute Lymphoblastic Leukemia: Results of Dfci All Consortium Protocol 05-001","volume":"2","author":"Vrooman","year":"2018","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-018-0701-0","article-title":"Long-Term Survivors of Childhood Cancer: Cure and Care\u2014the Erice Statement (2006) Revised After 10 Years (2016)","volume":"12","author":"Jankovic","year":"2018","journal-title":"J Cancer Surviv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560847","article-title":"Infection-Related Mortality in Children With Acute Lymphoblastic Leukemia: An Analysis of Infectious Deaths on Ukall2003","volume":"124","author":"O\u2019Connor","year":"2014","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus Definitions of 14 Severe Acute Toxic Effects for Childhood Lymphoblastic Leukaemia Treatment: A Delphi Consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401939","article-title":"Children's Cancer Group Trials in Childhood Acute Lymphoblastic Leukemia: 1983\u20131995","volume":"14","author":"Gaynon","year":"2000","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401973","article-title":"Long-Term Results of Four Consecutive Trials in Childhood All Performed by the All-Bfm Study Group From 1981 to 1995","volume":"14","author":"Schrappe","year":"2000","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1341","article-title":"Risk of Adverse Events in Children Completing Treatment for Acute Lymphoblastic Leukemia: St. Jude Total Therapy Studies Viii, Ix and X","volume":"9","author":"Pui","year":"1991","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048313","article-title":"Saving the Children\u2014Improving Childhood Cancer Treatment in Developing Countries","volume":"352","author":"Ribeiro","year":"2005","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2471","article-title":"Establishment of a Pediatric Oncology Program and Outcomes of Childhood Acute Lymphoblastic Leukemia in a Resource-Poor Area","volume":"291","author":"Howard","year":"2004","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22127","article-title":"Cost of Childhood Acute Lymphoblastic Leukemia Care in Shanghai, China","volume":"53","author":"Liu","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of Dasatinib Vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2002"},{"key":"B24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11684-020-0759-8","article-title":"Precision Medicine in Acute Lymphoblastic Leukemia","volume":"14","author":"Pui","year":"2020","journal-title":"Front Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-322909","article-title":"Escalating Intravenous Methotrexate Improves Event-Free Survival in Children With Standard-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group","volume":"118","author":"Matloub","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5936","article-title":"Minimal Residual Disease-Guided Treatment Deintensilication for Children With Acute Lyrnphoblastic Leukemia: Results From the Malaysia-Singapore Acuten Lymphobiastic Leukemia 2003 Study","volume":"30","author":"Yeoh","year":"2012","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment Reduction for Children and Young Adults With Low-Risk Acute Lymphoblastic Leukaemia Defined by Minimal Residual Disease (Ukall 2003): A Randomised Controlled Trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"key":"B28","article-title":"Evaluation of a Modified Induction Chemotherapy in Children With Acute Lymphoblastic Leukemia","volume":"45","author":"Pan","year":"2007","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401964","article-title":"Long-Term Follow-Up of Dutch Childhood Leukemia Study Group (Dclsg) Protocols for Children With Acute Lymphoblastic Leukemia, 1984\u20131991","volume":"14","author":"Kamps","year":"2000","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-011809","article-title":"Intrathecal Triple Therapy Decreases Central Nervous System Relapse But Fails to Improve Event-Free Survival When Compared With Intrathecal Methotrexate: Results of the Children's Cancer Group (Ccg) 1952 Study for Standard-Risk Acute Lymphoblastic Leukemia, Reported by the Children's Oncology Group","volume":"108","author":"Matloub","year":"2006","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401704","article-title":"Benefit of Intensified Treatment for All Children With Acute Lymphoblastic Leukaemia: Results From Mrc Ukall Xi and Mrc All97 Randomised Trials","volume":"14","author":"Hann","year":"2000","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12885-020-07752-x","article-title":"Reduced Intensity of Early Intensification Does Not Increase the Risk of Relapse in Children With Standard Risk Acute Lymphoblastic Leukemia-A Multi-Centric Clinical Study of Gd-2008-All Protocol","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004215","article-title":"Reduced\u2013Dose Intensity Therapy for Pediatric Lymphoblastic Leukemia: Long-Term Results of the Recife Rella05 Pilot Study","volume":"135","author":"Pedrosa","year":"2020","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4946","article-title":"Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (Aieop-Bfm All 2000)","volume":"36","author":"Schrappe","year":"2018","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"Pax5-Driven Subtypes of B-Progenitor Acute Lymphoblastic Leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3301","article-title":"The Genomic Landscape of High Hyperdiploid Childhood Acute Lymphoblastic Leukemia","volume":"47","author":"Paulsson","year":"2015","journal-title":"Nat Genet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-3233-2_13","article-title":"Mechanism of Etv6-Runx1 Leukemia","volume":"962","author":"Sundaresh","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.234","article-title":"Clinical Impact of Minimal Residual Disease in Children With Different Subtypes of Acute Lymphoblastic Leukemia Treated With Response-Adapted Therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.911567\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T05:05:23Z","timestamp":1654578323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.911567\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":38,"alternative-id":["10.3389\/fonc.2022.911567"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.911567","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"article-number":"911567"}}